Skip to main content

GeoVax Labs (NASDAQ: GOVX) — Company Overview, News & Financial Data

GeoVax Labs logo
GOVX GeoVax Labs
GeoVax Labs primary media
Company profile

GeoVax Labs

GeoVax Labs (NASDAQ:GOVX) is a biotechnology firm focusing on developing vaccines to address infectious diseases, cancers, and for use in immunotherapy. Traded on the NASDAQ stock exchange under the ticker code (NASDAQ:GOVX), the company leverages its unique Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform to produce vaccines that induce robust immune responses. GeoVax's projects span several critical areas, including HIV, COVID-19, Zika virus, hemorrhagic fever viruses, and malaria, alongside working on therapeutic vaccines for chronic Hepatitis B infections and solid tumors. The objective of GeoVax is not only to advance public health through preventive measures against infectious diseases but also to pioneer therapeutic vaccines that could potentially transform cancer treatment paradigms.

Snapshot

Public USOwnership
1988Year founded
17Employees
Atlanta, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Atlanta, US

Products and/or services of GeoVax Labs

  • Development of a preventive vaccine for COVID-19 using a modified vaccinia Ankara (MVA) vector platform.
  • HIV vaccines aimed at preventing and treating different clades of the HIV virus.
  • MVA-VLP vaccine platform targeting prevention of Zika virus infections.
  • Therapeutic vaccine research focused on chronic hepatitis B infection.
  • Ebola virus vaccine utilizing the MVA platform for prevention.
  • Collaborative efforts in immunotherapy for solid tumor cancers, leveraging its MVA technology.

GeoVax Labs executive team

  • David Alan DoddChairman, President & CEO
  • Mark J. NewmanChief Scientific Officer
  • Kelly T. McKee Jr.Chief Medical Officer
  • Mark W. ReynoldsCFO & Corporate Secretary
  • Thomas O'BrienVice President of Quality Systems & Compliance
  • Jeffrey WelchHead of Process Development & Manufacturing Operations
  • Valerie C. Montgomery RiceSpecial Advisor to the Chairman & CEO and Director
  • John W. SharkeyVice President of Business Development

Recent announcements

What GeoVax Labs (GOVX) has told the market, newest first.

Key financials

Reported results for GeoVax Labs, in USD.

Market cap
1M
Revenue (TTM)
0
P/E ratio
—
EPS (diluted, TTM)
-15.0
Dividend yield
—
Profit margin
0.0%
GeoVax Labs annual revenue and income
Fiscal year endRevenueOperating incomeNet income
2.5M-21.6M-21.5M
4M-25.1M-25M
0-26.7M-26M
81K-14M-14M